Less than one in 10 people that would benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it issues its initial advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that excess weight is a lifelong illness that can be addressed with comprehensive and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to widespread access to the injections that can aid individuals in losing significant weight, explains the body.
Skinny Jab Supply Crisis
Despite the current most favorable scenario, the production of such drugs could only cover approximately 100 million people – under 10% of eligible patients, as stated by the WHO.
The guideline encourages governments and firms to expand availability, through strategies such as voluntary licensing.
The intellectual property rights on semaglutide – the main component of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people reduce food intake.
People usually begin shedding pounds after several weeks of commencing the regular doses.
Studies points to users may see weight return after a year of discontinuing the drug, when their normal hunger come back.
Being carrying excess weight raises your risk for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight affects people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
